NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related…
$6.40+2.73%
报价 2026-11-13
市值
$29.3M
EV
$17.7M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -55.2%
$1.60$14.27
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NXTCNextCure, Inc. | $29.3M | +2.7% | -85.2% | 0% | – | – | – | |
| QTTBQ32 Bio Inc. | $260.6M | -1.2% | 0.0% | 99.8% | 3.1x | 4.5x | – | |
| ANTXAN2 Therapeutics, Inc. | $172.6M | +2.5% | +119.0% | 0% | – | – | – | |
| VRCAVerrica Pharmaceuticals Inc. | $61.2M | -4.3% | -28.3% | 85.9% | – | – | – | |
| BOLDBoundless Bio, Inc. | $59M | +1.6% | – | 0% | – | – | – | |
| TAOXTAO Synergies Inc. | $16.9M | -6.7% | – | 99.9% | – | – | – | |
| JSPRJasper Therapeutics, Inc. | $15.2M | +2.4% | -75.0% | 0% | – | – | – | |
| PLURPluri Inc. | $11.3M | -3.7% | – | 44.6% | – | – | – | |
| INTSIntensity Therapeutics, Inc. | $8.3M | -0.6% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -14.1% | 22.3% | 3.1x | 4.5x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。